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ABSTRACT
Changes over time in awareness of hepatitis C infection in the United States 2007-2018
By
Jennifer Lynn Mezzo
December 4, 2020
INTRODUCTION: An estimated 115 million people worldwide and 2.4-3.5 million people in the
United States are infected with Hepatitis C infection. The majority of these individuals are
unaware of their infection due to the asymptomatic nature of the disease and are therefore at
greater risk for advanced-staged complications such as cirrhosis or liver cancer.
AIM: This study aimed to measure changes over time in awareness of hepatitis C infection
among a housed, non-institutionalized representative sample within the United States.
METHODS: National Health and Examination Survey (NHANES) data spanning years 2007 – 2018
were compiled into one dataset. After eligibility restrictions were applied the final dataset
contained N=387 respondents. Bivariate and multivariate logistic regression models were
conducted to explore the associations between our independent variables and awareness of
HCV infection as well as to assess possible confounders and mediators of the relationship
between time (primary exposure variable) and awareness of HCV infection (outcome variable).
Bivariate linear regression was used to estimate linear trends to estimate linear trends in
awareness of HCV infection over time. We also assessed the percent of those aware of their
HCV infection to clearly define the outcome variable.
RESULTS: Awareness of one’s HCV infection increased from 24.53% in the 2007-2008 survey
cycle to 63.48% in the 2017-2018 survey cycle (β for trend 0.09, p<0.0001). The odds of
reporting a positive HCV diagnosis in the second survey period (2013-2018) was 3.71 times the
odds in the first time period (p <0.0001).
CONCLUSION: Diagnosed hepatitis C is increasing, however, remains suboptimal in the US.
Recent efforts may have contributed to these increases, bringing us closer to achieving DHHS
and WHO goals of viral hepatitis elimination.
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Introduction:
1.1.

Background
According to the World Health Organization (WHO), an estimated 115 million people

worldwide are infected with Hepatitis C (HCV) (WHO, 2016). In the US, an estimated 4.1 million
Americans are living with a past or current HCV infection, approximately 2.4-3.5 million of
whom have a current HCV infection (DHHS, 2017; Hofmeister, 2019). The majority of individuals
infected are baby boomers, or those born between 1945 and 1965; however, there has been an
increase in the number of individuals younger than 30 infected due to injection drug use,
contributing to a bimodal age distribution of HCV burden (Bush, 2019; Hofmeister, 2019).
Chronic HCV infection is a major cause of liver cirrhosis and liver cancer and claims the livers of
approximately 15,000 Americans each year (Al-Tayyib, 2009; Trooskin, 2015).
The majority of individuals infected with HCV are unaware of their infection due to the
silent nature of the disease in its early stages, and are therefore at greater risk for developing
cirrhosis, liver cancer, and premature mortality (Valdisermi, 2014). Several studies have found
that awareness of one’s HCV infection among Americans is suboptimal, between 50-55% (Kim,
2018; Volk, 2009; Zhou, 2020). The asymptomatic nature of the disease makes screening
essential to identify and get into treatment those individuals who are infected (Zhou, 2020). In
2014, several new drugs called direct-acting antivirals (DAAs) were approved by the FDA to treat
HCV (Trooskin, 2015). DAAs have a cure rate over 95% with fewer severe side-effects than
previous interferon treatments (Barua, 2015; Douglass, 2018; Trooskin, 2015). The emergence
and high cure rate of these DAAs increases the importance of screening for and diagnosing HCV.
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The largest barrier to increasing HCV and screening treatment is lack of diagnosis (Clark &
Muir, 2012). In addition to the asymptomatic nature of the disease, a lack of awareness about
the disease among providers, policymakers and the general public; the price of HCV treatment;
and lack of affordable treatment have been cited as barriers to accessing HCV screening and
care (Bruggmann, 2015; Clark, 2012; Ditah, 2015; Stopka, 2017; Valdisermi, 2014).
On March 23, 2010, the Patient Protection and Affordable Care Act (ACA) was signed into
law and intended to increase overall insurance coverage in the US (French, 2016). The ACA
utilized multiple strategies to increase access, including allowing young adults to remain on
parents insurance until age 26, requiring large employers to offer healthcare, requiring
individuals without employer sponsored insurance to purchase insurance or pay a penalty, and
the ACA also expanded Medicaid eligibility (French, 2016; McIntyre, 2019). McIntyre et al.
reported that since the law’s implementation in 2010, the number of uninsured people in the
US has fallen by about 20 million (2019). Additionally, significant improvements have been seen
in access to primary care services and medications since the ACA has been implemented
(French, 2016).
Another factor that may affect diagnosis of HCV infections is injection drug use (IDU)
and the current opioid epidemic. The estimated global prevalence of HCV among PWID is 67%,
and the countries with the greatest number of HCV injected PWID include China with 1.6
million, the US with 1.4 million, and Russia with 1.3 million affected (Bruggmann, 2015). In the
US, IDU is currently the primary risk factor for HCV transmission and the leading cause of HCV
incidence (Zibbell, 2018). Since 2009, the number of new HCV cases has risen dramatically,
largely among white adults in their twenties and thirties and particularly among those residing
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in nonurban areas (Liang and Ward, 2018; Zibbell, 2018). Abara et al. reported that 55% of
people who inject drugs (PWID) in 8 US cities were found to also have been infected with HCV,
including almost half of young PWID (18-35 years) (2019). Research evidence indicates that
there has been a significant increase in HCV infections among young people age 18-39, with IDU
being indicated in more than 80% of the HCV infections in one analysis (Zibbell, 2018).
Currently, there are few studies that assess awareness of one’s HCV infection, and none
that assess changes in awareness over time. Researchers have used National Health and
Nutritional Examination Survey (NHANES) data to determine awareness of participants’ HCV
infection (Kim, 2019; Zhou, 2020). NHANES conducts lab tests for HCV antigen and antibody on
survey respondents in addition to asking respondents whether they’ve been diagnosed or have
seen a doctor for their HCV diagnosis. This allows researchers to match the biomarkers from
the lab results with the survey questionnaires to estimate the percentage of people with HCV
infection who have been diagnosed, or are aware of their HCV infection. Kim (2019) found that
overall awareness of chronic HCV among NHANES participants was 55.6%, and Zhou (2020)
found there was a 49% awareness of HCV infection among respondents. Both authors used
NHANES survey years 2013-2016 to conduct their analysis and did not assess change over time.
1.2.

Purpose of Study

For this study, we will examine whether there are changes over time in awareness of HCV
infection using data from 6 NHANES survey cycles between 2007 and 2018 (2007-2008, 20092010, 2011-2012, 2013-2014, 2015-2016, and 2017-2018 administration periods). We will also
examine whether HCV diagnosis changed over time and look at potential confounders, effect
modifiers, and mediators to determine if 1) the prevalence of awareness of HCV infection
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increased over time; 2) if the increase was statistically significant; and 3) if there were any
confounders, mediators, or effect modifiers that influenced the association between awareness
of HCV infection and time.
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Literature Review
2.1.

Estimated Versus Actual Prevalence of HCV Infection
Hepatitis C is a leading cause of morbidity and mortality worldwide and represents a

major global public health concern (Stone, 2018). Abadie et al. estimates that worldwide, there
are an estimated 130 million people infected with HCV (2017). The World Health Organization
(WHO) estimates that 1.5 million new HCV infections occur annually, and 170 million people
worldwide are estimated to have chronic HCV (Douglass, 2018; Harris, 2013). In 2017, only 1.6
million patients were treated for HCV, speaking to the low number of individuals aware of their
infection, striking, given that an estimated 350,000 persons worldwide die due to HCV-related
liver diseases each year (Douglass, 2018; Harris, 2013).
Hepatitis C is the most common blood-borne infection in the US (Al-Tayyib, 2014;
Trooskin, 2015). An estimated 2.7 to 3.9 million persons are living with HCV infection, and the
majority do not know they are infected (Trooskin, 2015; Valdisermi, 2014). The Centers for
Disease Control and Prevention (CDC) estimates that up to 75% of individuals with HCV are not
aware of their infection, and this estimate is conservative as it is based on NHANES data and
does not include homeless individuals, those with unstable housing, or incarcerated individuals,
populations that are disproportionately affected by viral hepatitis (NASTAD, 2013). Further, it is
estimated that 80% of all HCV-infected individuals in the US will develop chronic HCV infection
and 20% will develop serious complications such as cirrhosis or HCC, requiring treatments such
as medication, hospitalization, and liver transplant (Bush, 2019; CDC 2017; Trooskin, 2015;
Valdisermi, 2014).
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CDC estimates that there are approximately 17,000 new HCV infections each year in the
US (Valdisermi, 2014). Without the necessary access to care and/or treatment, viral hepatitis
can lead to chronic liver disease, cirrhosis, liver cancer and liver failure and complications from
these chronic infections claim 15,000 lives annually (Al-Tayyib, 2014; NASTAD, 2013; Trooskin,
2015). The number of deaths attributed to HCV infection now surpasses the number of deaths
attributed to HIV (Al-Tayyib, 2014). There is a lack of knowledge and awareness surrounding the
seriousness of chronic viral hepatitis among healthcare providers, policy makers, and at-risk
populations and this, in combination with inadequate resources to combat this epidemic, has
impeded an effective national and global public health response (Valdisermi, 2014).
2.2.

Viral Hepatitis Elimination Goals
Worldwide, chronic viral hepatitis accounts for more deaths than that from HIV/AIDS,

tuberculosis, or malaria (Buckley, 2016; WHO, 2016). In the US, more than 20,000 deaths can
be attributed to viral hepatitis annually (CDC, 2013). In response, both the WHO and US
Department of Health and Human Services have developed viral hepatitis elimination plans
(DHHS 2017; WHO, 2016). The WHO aimed to reduce viral hepatitis infections to less than one
million and reduce deaths attributed to viral hepatitis to less than 500,000 worldwide by 2030
(WHO, 2016). One of the key areas of focus in the WHO plan is increasing viral hepatitis
diagnosis from less than 5% of chronic hepatitis infections (2015 baseline estimate) to 90% in
2030 (WHO, 2016). To do this, the WHO recommends integration of viral hepatitis testing into
national hepatitis policies, strengthening national laboratory systems so countries can provide
quality diagnosis of viral hepatitis, as well as establishing key linkages between testing and
other services to improve access to treatment and support services (WHO, 2016).
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By 2020, the US Department of Health and Human Services (DHHS) aims to decrease the
number of new HCV infections by at least 60% and increase the percent of persons aware of
their HCV infection to 66% (DHHS, 2017). DHHS estimates that 45% of people with HCV have
not been diagnosed (DHHS, 2017). The action plan calls for education of both providers and
individuals about screening as a first step in increasing awareness of one’s HCV infection status.
2.3.

The Patient Protection and Affordable Care Act

On March 23, 2010, the Patient Protection and Affordable Care Act (ACA) was signed into
law (French, 2016). The ACA built upon the existing employer-sponsored insurance system and
created new requirements for individuals, employers, health care providers, and insurance
companies to address access to health insurance, health care costs, and delivery of health care
(French, 2016). Multiple strategies were employed with the goal of increasing overall insurance
coverage: allowing young adults to remain on parents’ insurance plans until age 26; requiring
large employers to offer health insurance to full-time employees; requiring individuals without
employer-sponsored insurance to purchase insurance or pay a penalty; and expand Medicaid
eligibility to all individuals under age 65 with an annual income up to 400% of the federal
poverty level (French, 2016; McIntyre, 2019). The ACA also imposed new regulations on
insurance companies, including prohibiting companies from charging higher premiums or
denying coverage due to preexisting conditions, requiring insurance companies to provide
some preventive services without any cost sharing, and annual and lifetime limits on health
benefits were abolished (French, 2016; McIntyre, 2019; NVHR, N.D.).
The ACA provides opportunities to help prevent new viral hepatitis infections, and also treat
existing infections. Some of the features of the ACA related to viral hepatitis include access to
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viral hepatitis vaccinations (hepatitis A and B), improved provision of essential care and
treatment, a ban on denial of health coverage based on preexisting conditions, and required
coverage of recommended preventive services such as hepatitis B and C screening for
individuals in recommended risk categories (DHHS, 2017).
Early Findings
Several studies suggest that the ACA has substantially decreased the number of
uninsured Americans (French, 2016; McIntyre, 2019). Since the implementation of the ACA in
2010, the number of individuals without insurance in the US has decreased by about 20 million
people (McIntyre, 2019). Additionally, significant improvements in access to primary care
services, medications, affordability of care, and self-reported health were reported as early
findings in studies looking at the effectiveness of the ACA (French, 2016). The proportion of the
population without a regular source of health care decreased from 29.8% in 2013 to 26% in
2014, however, French reported that 40% of respondents still had at least one access problem,
especially for racial/ethnic minority and low income groups (French, 2016).
2.4.

The ACA and Access to Hepatitis Treatment

ACA and Hepatitis treatment
In 2014, several new drugs to treat HCV received FDA approval in the US (Trooskin,
2015). These direct-acting antivirals (DAAs) have a cure rate over 95% with a treatment
duration of only 8-12 weeks and fewer and less sever side-effects than interferon treatments
used previously (Barua, 2015; Douglass, 2018; Trooskin, 2015). These treatments, however, are
extremely expensive (up to approximately $40,000 per treatment course), and given the large
size of the population in need some insurers have restricted coverage (Douglass, 2018;
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Trooskin, 2015). This issue is especially relevant to the Medicare and Medicaid programs
because of the high burden of HCV infection in their covered populations, but other
populations covered through governmental funding are also disproportionately affected by
HCV, including those incarcerated and those receiving care through the VA (Bush, 2019;
Trooskin, 2015).
While the ACA stipulates that no insurer may deny coverage to someone based on preexisting or chronic health conditions, some insurers have included stipulations into their plans
that place limits on the types and amount of coverage those with HCV receive for their
condition, including excluding medications and placing drugs in the most expensive copay or
coinsurance tiers, making the cost prohibitive for many patients seeking treatment for their
HCV (NASTAD, 2013; Ryan, 2014). Additionally, insurers are not required to provide routine HCV
screening for baby boomers, and HCV screening is only required to be covered for pregnant
women (NASTAD, 2013).
Medicaid Coverage for HCV Treatment
One of the strategies employed in the ACA to expand health insurance coverage was the
expansion of Medicaid. As of 2018, 32 states had expanded their Medicaid programs (KFF,
2018). A literature review conducted by the Kaiser foundation found that states that expanded
their Medicaid programs experienced large reductions in uninsured rates beginning in 2014,
and these reductions far exceeded reductions seen in states that did not expand their Medicaid
programs (KFF, 2018). Kaiser also found that people with substance use disorders and people
with HIV were two populations that saw large reductions in uninsured rates (KFF, 2018).
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Despite these great strides seen in increasing health insurance coverage, individuals with
HCV, and especially injection drug users, experience significant barriers in gaining access to HCV
treatment while on Medicaid. Of the 42 states with known Medicaid reimbursement criteria for
sofosbuvir, one of the new DAA drugs available with a >90% cure rate for HCV, 88% of states
include drug or alcohol use in their eligibility criteria for reimbursement (Barua, 2015). This
means that patients with current (or historical substance use depending on the state) will be
ineligible for treatment, despite current clinical guidelines that have removed current IDU as an
exclusion criteria for treatment and is inconsistent with FDA-approved labeling for sofosbuvir
and evidence-based recommendations for treatment (Barua, 2015; Harris, 2013). Most states
require urine drug screening before treatment (Harris, 2013).
2.5.

The Opioid Epidemic and Hepatitis C
The US is currently in the midst of an opioid epidemic in which substantial challenges

are tied to prescription opioid addition, elevated heroin use, and an increasing number of HCV
infections, especially in younger populations, in addition to an overwhelming number of opioid
overdose deaths (Stopka, 2017). IDU is currently the primary risk factor for HCV transmission, as
well as the leading cause of incidence (Zibbell, 2018). The US saw a substantial increase in acute
HCV infections between 2004 and 2014 in persons age 18 to 39 years, with IDU the most
frequently cited risk factor in national surveillance data, and reported that 80% of case reports
with an HCV-related risk indicated IDU in 2014 (Zibbell, 2018. Abara et al (2019) reported that
55% of people who inject drugs (PWID) in 8 US cities were found to also have been infected
with HCV, including almost half of young PWID (18-35 years).
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Methods and Procedures
3.1.

Data Source and Sample

The National Center for Health Statistics (NCHS), part of the CDC, conducts the NHANES
survey annually with approximately 5,000 individuals participating in interviews,
questionnaires, and health examinations (NCHS, 2020a). NHANES is nationally representative,
with a target population of the noninstitutionalized civilian resident population in the US.
Several groups are oversampled, including Hispanic persons, Non-Hispanic Black persons, NonHispanic Asian persons, Non-Hispanic White and other persons at or below 185% poverty level,
and Non-Hispanic White and other persons age 80 and older. NHANES utilizes a complex,
multistage probability design, first selecting primary sampling units, then selecting segments
within the primary sampling units that contain a cluster of households, then selecting specific
households within those segments, and finally selecting individuals within a household (NCHS,
2020b).
For this analysis, six two-year survey cycles, 2007-2008, 2009-2010, 2011-2012, 2013-2014,
2015-2016, and 2017-2018 were combined and compared to identify changes in hepatitis C
diagnosis over time. For each of the survey periods, the following datasets were combined for
analysis: 1) demographics, 2) hepatitis C (laboratory), 3) current health status, 4) health
insurance, 5) hepatitis (questionnaire), 6) hospital utilization and access to care; 7)
immunization, 8) medical conditions, and 9) drug use.
We applied restrictions on the initial sample of individuals included in the six datasets
(N=57,414) to include only those participants who were age 20 and older and received a
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positive HCV RNA test result. After applying our inclusion/exclusion criteria, there were a total
of 387 respondents in our sample.
The datasets utilized contain secondary public use data and therefore do not require IRB
approval. NHANES data is a pre-approved data source per IRB policies and guidelines at GSU
(GSU, 2019). Secondary data were used for this study because it is cost-effective and less time
consuming than it would be to conduct primary data collection for this topic. NHANES is
nationally representative and collects data on measures that were used to conduct this
analysis.
3.2.

Key Variables of Interest
The following section presents the variables of interest for this study.

Dependent Variable
The dependent variable for this study is diagnosed hepatitis C infection, measured by
diagnosis of HCV. To create this variable, we used the variable “ever told you have hepatitis C”
for survey years 2013-2018 and the variable “seen a doctor about test result?” for survey years
2007-2012 for the numerator and divided this by the number of respondents with a positive
RNA test. The outcome is expressed as a proportion.
Independent Variables
To answer our research questions, we looked at several independent variables, as
described below. Our primary independent variable, or exposure of interest was survey period.
We also assessed several additional variables as potential confounders. Finally, test our
hypothesis that ACA implementation would increase awareness of HCV infection, we assessed
health insurance coverage as a potential mediator of this association.
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Primary Independent Variable
Survey Period: For our primary exposure variable we looked at the differences in diagnosed
hepatitis C across survey periods (2007-2018). We also developed a dichotomous variable to
compare survey periods between 2007-2012 and 2013-2018.
Independent Variables Assessed as Potential Confounders or Mediators
Demographics: Demographic variables included age, gender, marital status, race/ethnicity,
poverty income ratio (PIR), and education level. Age was reported as the respondent’s age in
years at the time of the interview. Gender was classified into two groups, male and female.
Race/ethnicity was reported as Mexican American, Other Hispanic, non-Hispanic White, NonHispanic Black, and other race-including multi-racial. NHANES asks respondents their highest
level of education completed or highest degree received. For this analysis, education level was
categorized as the following: less than 5th grade education; less than 9th grade education; some
high school completed; high school diploma (or equivalent); some college; or college graduate.
For marital status, NHANES collects information about whether participants are married,
widowed, divorced, separated, never married, or living with a partner. For this analysis, we
classified marital status into two groups: married or not married. Finally, poverty income ratio
(PIR) was calculated using family income, and poverty guidelines by family size dependent on
state of residence and year. For this analysis, PIR was divided into two categories: at or below
poverty level (0-4.00) and above poverty level (greater than 4.00).
Drug Use: Drug use variables included lifetime illicit drug use (cocaine, heroin,
methamphetamine) and lifetime IDU. Lifetime use of cocaine/heroin/methamphetamine and
IDU were reported as yes or no.
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Health Insurance: Health insurance variables included health insurance coverage and type of
health insurance. Health insurance coverage was reported as yes or no. To collect the type of
health insurance a participant has, NHANES asks a series of questions to determine the type of
insurance plan by which a participant is covered. Response options include private insurance,
Medicare, Medi-Gap, Medicaid, CHIP, military health care, state-sponsored health plan, other
government insurance, Indian Health service, single service plan, or no coverage of any type.
Access to Healthcare: The access to care variable used for this analysis was routine place to go
for healthcare. For this variable, NHANES reported the following response options: yes, there is
no place, and there is more than one place. We created a dichotomous variable combining
options for yes and there is more than one place.
Hepatitis Vaccinations: Hepatitis vaccination variables included hepatitis A and hepatitis B
vaccinations. For hepatitis A, NHANES categorized responses as those who received at least 2
doses, those who received less than 2 doses, and those who received no doses. For hepatitis B,
NHANES categorized responses as those who received at least 3 doses, those who received less
than 3 doses, and those who received no doses. For both HAV and HBV vaccinations we created
a dichotomous variable with options yes (those who received at least one dose of the vaccine)
and no (those who did not receive any doses of the vaccine).
Ever tested for HIV virus: This variable was used as a proxy for sexual risk. NHANES reported
responses as yes or no.
Blood Transfusion: For this category we looked at receipt of a blood transfusion. Response
options for this variable included yes or no.
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Chronic Disease: Chronic disease variables included asthma, coronary heart disease,
emphysema, bronchitis, and liver condition. For each of these variables, responses were
categorized as yes or no.
3.3.

Statistical Analysis

SAS version 9.4 was used to conduct all analyses. Descriptive statistics were conducted for all
participant characteristics including age, gender, race, marital status, education, income, and
insurance coverage. Bivariate analyses were conducted using Chi-square tests and were
reported as odds ratios.
Bivariate and multivariate logistic regression models were conducted to explore the
associations between our independent variables and awareness of HCV infection as well as to
assess possible confounders and mediators of the relationship between time (primary exposure
variable) and awareness of HCV infection (outcome variable). Bivariate linear regression was
used to estimate linear trends to estimate linear trends in awareness of HCV infection over
time. Survey years were combined to develop a dichotomous variable (2007-2012 and 20132018) for measuring time as exposure of interest. Potential confounders and mediators were
evaluated for the relationship between time and awareness of HCV infection, our outcome
variable. Findings were reported as unadjusted and adjusted odds ratios. Statistical significance
was determined using 95% confidence intervals and p-values<.05.
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Results
4.1.

Study Sample

Of the 387 individuals included in our study, 32.82% were female. The mean age of
participants was 54.46 (95% CI: 53.38,55.53), and the racial/ethnic make-up of the sample
included 39.53% non-Hispanic Black, 37.73% non-Hispanic White, 9.56% Mexican American,
8.53% Other Hispanic, and 4.65% other race. One hundred and twenty five (32.30%) of the 387
participants reported being married, and 215 (55.84%) reported having attended some college
or having received a college degree or higher. Table 1 below provides demographic and risk
factor characteristics of study participants.
There were 142 participants (36.69%) who reported awareness of their HCV infection. We
divided the NHANES survey cycles into 2 time periods, the first using survey cycles between
2007 and 2012 and the second survey cycles between 2013 and 2018. The odds of reporting a
positive HCV diagnosis in the second survey period (2013-2018) was 3.71 times the odds in the
first time period (p <0.0001). In the first survey period, 2007-2012, 52 (23.74%) respondents
reported a positive HCV diagnosis, while in the second survey period, 2013-2018, 90 (53.57%)
respondents reported a positive HCV diagnosis. Among those reporting lifetime injection drug
use, 51.34% reported being aware of their positive HCV infection (OR 1.8, p=0.02). Among
those who were older than 50 years of age, 40.68% reported awareness of their HCV infection
(OR 1.74, p=0.02), and 40.08% of those who were not married reported being aware of their
HCV infection (OR 1.59, p=0.04). Finally, the odds of reporting a positive HCV diagnosis among
those covered by health insurance was 0.55 times the odds of those not covered by health
insurance (p =0.01).
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Table 1: Participant Characteristics by Awareness of HCV Infection
Aware of HCV
Not Aware of
Infection+
HCV Infection+
Frequency (unweighted %)
N=142
N=245
NHANES Survey Implementation Period
Survey Cycles 2007-2012
52 (23.74)
167 (76.26)
Survey Cycles 2013-2018
90 (53.57)
78 (46.43)
Age
Less than/equal to 50 years
35 (28.23)
89 (71.77)
Older than 50 years
107 (40.68)
156 (59.32)
Sex
Female
41 (32.28)
86 (67.72)
Male
101(38.85)
159 (61.15)
Race
Other, including Multi-racial
86 (36.75)
148 (63.25)
Non-Hispanic Black
56 (36.60)
97 (63.40)
PIR
Greater than 4.00
11 (39.29)
17 (60.71)
Less than or equal to 4.00
131 (36.49)
228 (63.51)
Education
Some college or above
80 (37.21)
135 (62.79)
High school diploma or below
53 (35.57)
96 (64.43)
Marital Status
Married
37 (29.60)
88 (70.40)
Not married
105 (40.08)
157 (59.92)
Lifetime injection drug use
No lifetime injection drug use
51 (36.96)
87 (63.04)
Yes, has ever injected drugs
57 (51.35)
54 (48.65)
Lifetime Illicit drug use
No
32 (36.36)
56 (63.64)
Yes
77 (46.67)
88 (53.33)
Covered by health insurance
Yes
109 (40.98)
157 (59.02)
No
33 (27.50)
87 (72.50)
Type of health insurance
Private insurance
26 (32.91)
53 (67.09)
Public insurance
82 (44.09)
104 (55.91)
Routine place to go for healthcare
Yes
118 (38.19)
191 (61.81)
No
24 (30.77)
54 (69.23)
Received HAV vaccine
Yes
34 (39.53)
52 (60.47)
No
94 (35.61)
170 (64.39)
Received HBV vaccine
Variable
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OR*

P-value

1
3.71

<0.0001

1
1.74

0.02

1
1.33

0.21

1
0.99

0.98

1
0.88

0.77

1
0.93

0.75

1
1.59

0.04

1
1.8

0.02

1
1.53

0.12

1
0.55

0.01

1
1.6

0.09

1
0.72

0.23

1
0.85

0.51

Variable

Aware of HCV
Infection+
N=142
45 (45.92)
83 (33.20)

Not Aware of
HCV Infection+
N=245
53 (54.08)
167 (66.80)

OR*

P-value

Frequency (unweighted %)
Yes
1
0.03
No
0.59
Ever tested for HIV virus**
No
34 (26.15)
96 (73.85)
1
0.0009
Yes
98 (43.95)
125 (56.05)
2.21
Ever received blood transfusion
No
93 (33.82)
182 (66.18)
1
0.07
Yes
44 (44.00)
56 (56.00)
1.54
Risk factor: Chronic Asthma
No
112 (35.22)
206 (64.78)
1
0.2
Yes
30 (43.48)
39 (56.52)
1.41
Risk factor: CHD
No
137 (36.73)
236 (63.27)
1
0.98
Yes
4 (36.36)
7 (63.64)
0.98
Risk factor: Chronic Emphysema
No
133 (36.14)
235 (63.86)
1
0.32
Yes
9 (47.37)
10 (52.63)
1.59
Risk factor: Chronic Bronchitis
No
124 (35.33)
227 (64.67)
1
0.18
Yes
16 (47.06)
18 (52.94)
1.63
+ Awareness of HCV infection variable developed by using NHANES hepatitis questionnaire variables HEQ030
(2013-2018) or HCQ070 (2007-2012) and dividing by the number of RNA positives (NHANES laboratory variable
LBXHCR)
* Reference value is 1.00
** Proxy measure for sexual risk

4.2.

Changes Over Time in Awareness of HCV Infection
Table 2 below provides the percent of awareness of HCV infection in our sample and

corresponding 95% confidence intervals for each 2-year survey cycle. Awareness of HCV
infection increased from 24.53% (95% CI: 10.40, 38.66) in the 2007-2008 survey cycle to 63.48%
(95% CI: 48.03, 78.93) in the 2017-2018 survey cycle, and this increase was significant (β for
trend 0.09, p<0.0001).
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Table 2: Percent of Awareness of HCV Infection by NHANES Survey Period
NHANES Survey Period
Percent Aware+
95% Confidence Interval
2007-2008
24.53%
(10.40, 38.66)
2009-2010
16.10%
(2.66, 29.55)
2011-2012
22.77%
(14.97, 30.57)
2013-2014
54.28%
(35.30, 73.25)
2015-2016
56.85%
(38.37, 75.32)
2017-2018
63.48%
(48.03, 78.93)
+Weighted percent using survey procedures in SAS

To assess change over time we compared participant characteristics in the first survey
period (survey cycles between 2007 and 2012) and second survey period (survey cycles
between 2013 and 2018) to identify any significant differences among people with chronic HCV
between the time periods. Table 3 below describes participant characteristics and risk factors
by NHANES survey period. Odds ratios and p-values were calculated for each characteristic
measured. Several demographic characteristics were significantly associated with survey
period, including age (OR 2.46, p <0.0001), poverty-to-income ratio (OR 3.83, p= 0.0046), and
marital status (OR 1.93, p=0.0036). Type of health insurance, private vs. public, was also
significantly associated with survey period (OR 1.92, p=0.018).
Table 3: Participant Characteristics and Risk Factors by NHANES Survey Period
Variable
NHANES Survey NHANES Survey
OR*
Cycles 2007Cycles 2013-2018
N=168
2012
Frequency (unweighted %)
N=219
Aware HCV Positive+
No
167 (76.26)
78 (46.43)
1
Yes
52 (23.74)
90 (53.57)
3.71
Age
Less than/equal to 50 years
88 (40.18)
36 (21.43)
1
Older than 50 years
131 (59.82)
132 (78.57)
2.46
Sex
Female
78 (35.62)
49 (29.17)
1
Male
141 (64.38)
119 (70.83)
1.34
Race
Other, including Multi-racial

130 (59.36)
26

104 (61.90)

1

P-value

<0.0001

<0.0001

0.18

0.61

Variable
Frequency (unweighted %)
Non-Hispanic Black
PIR
Greater than 4.00
Less than or equal to 4.00
Education
Some college or above
High school diploma or below
Marital Status
Married
Not married
Lifetime injection drug use
No lifetime injection drug use
Yes, has ever injected drugs
Lifetime Illicit drug use
No
Yes
Covered by health insurance
Yes
No
Type of health insurance
Private insurance
Public insurance
Routine place to go for healthcare
Yes
No
Received HAV vaccine
Yes
No
Received HBV vaccine
Yes
No
Ever tested for HIV virus**
No
Yes
Ever received blood transfusion
No
Yes
Risk factor: Chronic Asthma
No

NHANES Survey
Cycles 20072012
N=219
89 (40.64)

NHANES Survey
Cycles 2013-2018
N=168

OR*

64 (38.10)

0.9

23 (10.50)
196 (89.50)

5 (2.98)
163 (97.02)

1
3.83

0.0046

112 (55.45)
90 (44.55)

103 (63.58)
59 (36.42)

1
0.71

0.12

84 (38.36)
135 (61.64)

41 (24.40)
127 (75.60)

1
1.93

0.0036

62 (57.94)
45 (42.06)

76 (53.52)
66 (46.48)

1
1.2

0.49

39 (35.45)
71 (64.55)

49 (34.27)
94 (65.73)

1
1.05

0.84

145 (66.21)
74 (33.79)

121 (72.46)
46 (27.54)

1
0.74

0.19

52 (35.86)
93 (64.14)

27 (22.50)
93 (77.50)

1
1.92

0.018

180 (82.19)
39 (17.81)

129 (76.79)
39 (23.21)

1
1.4

0.19

50 (25.38)
147 (74.62)

36 (23.53)
117 (76.47)

1
1.11

0.69

59 (29.95)
138 (70.05)

39 (25.83)
112 (74.17)

1
1.23

0.4

76 (37.62)
126 (62.38)

54 (35.76)
97 (64.24)

1
1.08

0.72

154 (72.30)

121 (74.69)

1

0.6

59 (27.70)

41 (25.31)

0.88

180 (82.19)

138 (82.14)

1
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P-value

0.99

Variable

NHANES Survey
Cycles 20072012
N=219
39 (17.81)

NHANES Survey
Cycles 2013-2018
N=168

OR*

P-value

Frequency (unweighted %)
Yes
30 (17.86)
1
Risk factor: CHD
No
212 (97.25)
161 (96.99)
1
0.88
Yes
6 (2.75)
5 (3.01)
1.1
Risk factor: Chronic Emphysema
No
210 (95.89)
158 (94.05)
1
0.41
Yes
9 (4.11)
10 (5.95)
1.48
Risk factor: Chronic Bronchitis
No
200 (91.32)
151 (90.96)
1
0.9
Yes
19 (8.68)
15 (9.04)
1.05
+ HCV diagnosis variable developed by using NHANES hepatitis questionnaire variables HEQ030 (2013-2018) or
HCQ070 (2007-2012) and dividing by the number of RNA positives (NHANES laboratory variable LBXHCR)
* Reference value is 1.00
** Proxy measure for sexual risk

4.3.

Factors Associated with HCV Diagnosis
We used bivariate and multivariate logistic regression models to assess the association

between the outcome (awareness of HCV infection) and exposure (survey implementation
period) in the analysis described above Multivariate logistic regression models were used to
assess potential confounders and mediators. Potential confounders identified and included in
our model were age and marital status. In the bivariate analysis, being older than 50 years was
associated with HCV diagnosis (OR=1.74, 95% CI: 1.10, 2.77). Not being married was also
associated with HCV diagnosis (OR=1.59, 95% CI: 1.01, 2.51). Other demographic and risk factor
variables examined, including race/ethnicity, lifetime injection drug use, type of health
insurance, receipt of hepatitis A or B vaccine, and poverty-to-income ratio were not significantly
associated with HCV diagnosis in this population. After adjusting for potential confounders,
neither age nor marital status remained significant factors in the association between NHANES
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survey implementation period and awareness of HCV infection. Table 4 below provides the
unadjusted and adjusted odds ratios for the bivariate and multivariate analysis.
To examine our hypothesis that implementation of the ACA mediated the relationship
between time and awareness of one’s HCV infection, health insurance coverage was examined
as a potential mediator. However, the increase in HCV diagnosis was not mediated by increases
in health insurance coverage.
Variable

Table 4: Factors Associated with Awareness of HCV Infection
Unadjusted OR+
P-value** AOR+ (95% CI)
(95% CI*)

NHANES Survey Implementation Period
Survey Cycles 2007-2012
Survey Cycles 2013-2018
Age
Less than/equal to 50 years
Older than 50 years
Marital Status
Married
Not married

1.00
3.71
(2.40,5.72)
1.00
1.74
(1.10,2.77)
1.00
1.59
(1.01,2.51)

*CI – confidence interval
** p-value statistically significant when P is 0.05 or less
OR – Odds Ratio
AOR – Adjusted Odds Ratio
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<0.0001

0.02

0.04

P-value**

1.00
4.633
(2.49,8.62)

<0.0001

1.00
1.11
(0.58, 2.10)

0.76

1.00
1.52
(0.88, 2.61)

0.13

Discussion
This study examined NHANES data for years 2007-2018 to assess changes in HCV diagnosis
and demographics and risk factors associated with HCV diagnosis over time. This analysis
demonstrates that HCV diagnosis has been increasing over time in the US. We found that in all
survey periods (2007-2018), 36.69% of participants reported knowledge of their HCV diagnosis.
We saw a significant increase in HCV diagnosis over time, with 24.53% of participants reporting
HCV diagnosis in the 2007-2008 NHANES survey cycle, compared to 63.48% of participants
reporting an HCV diagnosis in the 2017-2018 survey cycle. These findings illustrate progress
toward DHHS and WHO viral hepatitis elimination goals (DHHS, 2017; WHO 2016).
We tested for mediation of the relationship between time and awareness of HCV infection
by insurance status. However, in this analysis the increase of awareness of HCV infection was
not mediated by health insurance coverage. It is possible the increase we saw can be attributed
to participant misreporting of self-reported survey items, measurement error in the analysis, or
the small sample size, which did not provide enough power to see an association that may have
been present.
While our analysis could not attribute a specific factor to the increase in HCV diagnosis,
there are several potential factors that could explain this significant increase in HCV awareness.
First, the ACA was implemented in 2010 with options and implementation commencing
throughout 2011-2013 (Cauchi, 2013). The purpose of the ACA was to increase the number of
Americans with health insurance, thereby increasing their access to care. If more Americans are
able to access healthcare they may be more likely to ask for, or have a provider recommend,
HCV screening. However, this was not borne out of this analysis. It’s possible this is because the
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NHANES survey does not collect data on a representative sample of those most affected by
HCV, for example IDU, homeless individuals, or those who are incarcerated. So, it’s possible we
did not capture enough individuals with HCV infection to see an increase in awareness that was
due to increased health insurance coverage or access to care. It’s also possible that since
neither our health insurance coverage nor access to health care variables were significantly
associated with survey period, those who participated in the NHANES survey already had health
insurance and a place to go for healthcare prior to the implementation of the ACA.
Additionally, the current opioid epidemic and associated increases in injection drug use has
been attributed to increases in HCV infections (Zibbell, 2018) and may be associated with
increased awareness of HCV diagnosis, even though we were not able to show that with this
analysis.
Receiving a diagnosis, being aware of one’s HCV infection, is an important first step toward
achieving elimination goals laid out by the US DHHS (DHHS, 2017) and the WHO (WHO, 2016b).
There have been several initiatives focusing on enhancing HCV screening and diagnosis in the
US. For example, in 2020 the CDC revised previous birth cohort screening recommendations to
provide guidance that all adults age 18 and older should receive HCV screening at least once in
their lifetime and that women should receive HCV screening during each pregnancy except
where the prevalence of HCV is less than 0.1% (Schillie, 2020). There have also been a number
of awareness campaigns implemented recently to increase HCV screening among high-risk
populations. (CDC Foundation, N.D.; Veterans Affairs, 2020). But, the benefits of knowing one’s
diagnosis may extend beyond receipt of antiviral treatment. Left untreated, individuals with

31

chronic hepatitis C may be at greater risk for developing cirrhosis, liver cancer, and even
premature mortality (Valdisermi, 2014).
There are several limitations to this study. First, NHANES sampling does not capture several
groups of individuals, including institutional populations and homeless individuals. Additionally,
groups with a higher risk of viral hepatitis, injection drug users as an example, are generally
underrepresented or not captured. Second, NHANES uses a cutoff of 20 years and older for
“adult”. This does not account for the rising viral hepatitis infections among young injection
drug and opiate users. This likely leads to an underestimation of the proportion of the
population that is unaware of their HCV diagnosis, which may have skewed the results of our
analysis. Third, because NHANES utilizes a self-report design, it is possible that stigmatized
behaviors, such as injection or illicit drug use are underreported. Fourth, the small sample size
in our study may have resulted in an inability to show some important associations that would
have been apparent had our sample been larger. Fifth, between the 2011-2012 and 2013-2014
survey administration periods, NHANES changed the hepatitis questionnaire, and therefore, the
variable we used to develop the numerator for our outcome variable changed from “seen a
doctor about a test result” (HCQ070) to “Ever told you have hepatitis C?” (HEQ030). Because of
the use of different variables at different time points, it’s possible this change introduced
measurement error into our analysis. Finally, the two variables we hypothesized would mediate
the relationship between time and awareness of HCV infection, insurance status and injection
drug use, did not. These are both self-reported and are subject to mis-reporting and
measurement error/information bias.
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This study provides a snapshot of the current progress of eliminating hepatitis C in the US.
As discussed, diagnosis of one’s HCV infection remains inadequate at 63.48% in this analysis.
This finding is supported by previous research highlighting the low awareness of viral hepatitis
infections in this country (Kim, 2018; Volk, 2009; Zhou, 2020). Our analysis found an increasing
trend in HCV diagnosis, which is encouraging. As this analysis did not include institutionalized
populations or homeless individuals, and individuals at high risk for HCV (e.g., injection drug
users) are often underrepresented in NHANES surveys, it is important for additional studies to
build on these findings by including those populations in the analysis. This will build a more
complete picture of the true gaps between the prevalence of HCV and awareness of one’s HCV
infection in the US. Future research and interventions should also focus on scaling-up screening
and linkage to care campaigns across the US and educating healthcare providers about the
revised CDC recommendation (Schillie, 2020) that all adults should be screened for HCV in order
to increase awareness of HCV infection and get infected individuals into care for appropriate
HCV treatment.
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